Does Insurance Cover Zepbound? How to Check and Appeal a Denial

Most people with commercial insurance cannot get Zepbound covered in 2026. As of July 2026, 60% of commercially insured people had no coverage for Zepbound at all, up from 51% in 2025, which leaves over 114 million people without coverage ^[1][13]. Among those whose plans do cover weight-loss GLP-1 medications, 88% still face prior authorization or step therapy before the plan will pay ^[1][2].

To find out where your own plan stands, call the phone number on your prescription ID card and ask three things: whether Zepbound is on the formulary, whether it requires prior authorization or step therapy, and what your copay or coinsurance would be ^[10][12][15]. If you are denied, the fix depends on which of three denials you received: a formulary exclusion, a prior authorization denial, or a step therapy requirement. Each has a different remedy, and your denial notice is the starting point ^[13].

How many people have Zepbound coverage in 2026?

The GoodRx Research team tracks commercial insurance coverage for weight-loss medications using formulary data from MMIT, a healthcare analytics firm whose data reflects drug coverage for more than 190 million people ^[1][2]. The tracker was last updated July 10, 2026 ^[1].

Coverage for Zepbound has tightened three years in a row:

Year (snapshot)	No coverage	Restricted coverage	Unrestricted coverage
2024 (November 2024)	18.3%	72.5%	9.2%
2025 (August 2025)	50.5%	44.7%	4.8%
2026 (July 2026)	59.5%	36.8%	3.7%

All figures from GoodRx’s MMIT-based tracker ^[1]. Restricted coverage means the plan requires prior authorization, step therapy, or both before it will pay ^[1].

The number of people with no Zepbound coverage grew by about 17 million between 2025 and 2026, an 18% rise, to more than 114 million ^[1][13]. Nearly 13 million people, about 7% of the commercially insured, have no coverage for any weight-loss GLP-1 or GIP medication, meaning Wegovy, Zepbound, Foundayo, or Saxenda would all be excluded ^[1].

An earlier snapshot of the same tracker, reported by NPR in April 2026, found that 12 million people had lost Zepbound coverage and 12 million had lost Wegovy coverage from 2025 to 2026 ^[2]. The July 2026 update shows a larger uncovered count for Zepbound; the two figures are different vintages of one tracker, not competing claims ^[1][2].

For comparison, Wegovy in 2026 has 14.2% with no coverage, 76.7% restricted, and 9.1% unrestricted, with 27 million people still uncovered even as 1.6 million gained some form of coverage ^[1]. Mounjaro, the tirzepatide product prescribed for type 2 diabetes, has 0.4% with no coverage and 22.0% unrestricted in 2026 ^[1]. Foundayo, the oral GLP-1 approved by the FDA in April 2026, has 34.5% of commercially insured people with no coverage, over 66 million ^[1].

Why do so many plans not cover Zepbound?

Whether Zepbound is covered depends on three separate decisions, and each one can block coverage on its own.

First, your employer has to buy the weight-loss benefit. A Business Group on Health survey completed in February and March 2026 by 105 employer members found that 67% cover GLP-1s for weight management, while most cover them for diabetes ^[3]. Of those covering them for weight management, 72% said they were likely to continue in 2027 and 10% said they likely would not, and companies not covering them today are unlikely to add coverage ^[3]. A separate International Foundation of Employee Benefit Plans survey found that 60% of employers cover GLP-1s for diabetes only, while 36% cover both diabetes and weight loss, and 45% cover other FDA-approved conditions such as sleep apnea ^[4]. Nearly 8 in 10 employers in the Business Group survey said GLP-1s are driving increases in their healthcare costs ^[3].

Second, the pharmacy benefit manager (PBM) has to list the drug on the formulary it manages for your employer. Express Scripts states plainly that not all medications listed on its formulary documents are covered by all prescription plans, and that the plan sponsor decides ^[10][11]. Optum Rx says tiers and costs are set by the employer or plan sponsor, and the benefit plan decides how flagged drugs are covered ^[12].

Third, even when the drug is listed, the plan can require prior authorization, step therapy, or both. Employers use tactics such as validating clinical eligibility with biometric data, requiring participation in a weight-management program, limiting which providers can prescribe, and excluding certain medications from the formulary ^[3].

Cost pressure is the common thread. GLP-1s accounted for 6.9% of annual claims in 2023 and 11.4% in 2026, per the IFEBP survey, and the top factor in employers’ coverage decisions is a broker, consultant, or PBM recommendation, cited by 58% ^[4].

Do ACA Marketplace plans cover Zepbound?

Marketplace plans are the hardest place to find coverage. An analysis by Leverage|Axiaci, funded by the Robert Wood Johnson Foundation, reviewed the policies of all 300 carriers offering 2026 Marketplace plans for Wegovy, Zepbound, and Saxenda ^[5].

Only 26 of the 300 carriers cover GLP-1s for obesity in 2026 ^[5]. Those plans exist in nine states: California, North Dakota, New York, Vermont, Pennsylvania, West Virginia, Rhode Island, Delaware, and Georgia. In California and North Dakota, all carriers offer plans that cover GLP-1s ^[5].

The conditions are strict. All but four carriers limit coverage to people with a BMI of 40 and above, and all require documentation of three to nine months in a diet and exercise program plus proof that the enrollee was unable to lose weight ^[5]. Marketplace enrollees with weight-loss GLP-1 coverage fell from 3.6 million in 2024 to 2.8 million in 2026, and fewer than 10% of the 24.5 million people enrolled in ACA plans in 2025 would have coverage if they re-enrolled in 2026 plans ^[5].

How do I check if my own plan covers Zepbound?

Start with the phone number printed on your prescription ID card. Express Scripts, Optum Rx, and Lilly all direct readers there for plan-specific coverage questions ^[10][12][15]. Ask whether Zepbound is covered, whether prior authorization or step therapy applies, and what your cost would be after any deductible.

Lilly also offers a coverage-check tool on zepbound.lilly.com. Lilly describes the result as an estimate only, not a guarantee, and says to confirm details with your insurer directly ^[15].

Then look at the formulary document itself. A formulary is the list of medications a plan covers, and it changes during the year. CVS Caremark updates its formulary quarterly and announces changes a few months before the effective date ^[6]. Optum Rx medications may move to a higher tier or be excluded on January 1 or July 1 of each year, and may move to a lower tier at any time ^[12]. Express Scripts notes that brand-name medications may move to nonformulary status if a generic equivalent launches mid-year ^[10].

When you get an answer, figure out which of the three denial types you are dealing with, because the remedy differs: a formulary exclusion means the drug is not on the covered list at all; a prior authorization denial means it is covered in principle but your documentation did not meet the plan’s criteria; and step therapy means the plan wants you to try another drug first ^[13].

How do I read PA, QL, ST, and Tier E codes on a formulary?

Optum Rx formularies flag medications with letter codes. PA means prior authorization, so your doctor must give Optum Rx more information before the plan decides coverage. QL means quantity limit. ST means step therapy, meaning the plan requires trying lower-cost medications first. SP means the drug is designated as specialty. A double plus sign means coverage is determined by your prescription benefit plan. Tier E means the medication is excluded, which means it may not be covered or may need prior authorization ^[12].

Optum Rx tiers run from Tier 1, lower-cost generics and some brands, through Tier 2, mid-range preferred brands, and Tier 3, higher-cost brands, up to Tier E for excluded drugs ^[12]. On high-deductible plans, tier costs apply only after the deductible is met ^[12]. If a drug is not listed in the formulary at all, Optum Rx says to call the number on your member ID card or check your plan’s website ^[12].

On the Express Scripts 2026 National Preferred Formulary, brand names appear in CAPITALS, [INJ] marks injectables, and [SP] marks specialty medications ^[10].

Does CVS Caremark cover Zepbound?

It depends on the year and the formulary. CVS Caremark announced on May 1, 2025 that it would remove Zepbound from its standard control, advanced control, and value template formularies effective July 1, 2025, making Wegovy the preferred option for obesity ^[7][8][6]. Other formulary options in the category included orlistat, Qsymia, and Saxenda ^[6]. Mounjaro, the tirzepatide product for type 2 diabetes, was unaffected ^[7][6].

Caremark manages prescription benefits for roughly 25 to 30 million Americans, so the change reached a large population ^[7]. Truveta Research found that 9.6% of patients on anti-obesity tirzepatide switched drugs between June and July 2025, a 16-fold rise compared with the January-to-April average of 0.6%. Among those who switched, 82.8% moved to anti-obesity semaglutide and 0.9% to Mounjaro, while 90.4% stayed on tirzepatide. Truveta describes these as preliminary findings, not peer reviewed, based on data through August 27, 2025 ^[7].

CVS Caremark is adding Zepbound back to its standard formulary in October 2026, after removing it the year before ^[1].

Caremark has said its formulary strategy uses competition to drive down costs while maintaining clinically appropriate coverage, and that the high list prices set by drug manufacturers are the single biggest barrier to patient access ^[2][8].

How does the CVS Caremark formulary exception work?

Caremark’s published exception process, described in a Massachusetts Group Insurance Commission notice, offers a route for members who tried Wegovy and either had severe or intolerable side effects or did not lose enough weight ^[6].

A member can contact CVS Customer Care to request that a formulary exception form be sent to their prescriber, but only the prescriber may submit the required clinical documentation, by fax or, where available, electronic prior authorization ^[6]. The review considers whether the member previously tried and failed Wegovy or cannot take it. Failure means the member tolerated Wegovy but had an inadequate treatment response ^[6].

For weight management, the criteria require participation in a comprehensive weight-management program for at least 6 months before therapy, use with a reduced-calorie diet and increased physical activity, and documentation of BMI or current height and weight. For continuation, documentation must show at least 5% loss of baseline body weight, or maintenance of that loss ^[6].

For obstructive sleep apnea, the criteria require the medication to be used with a reduced-calorie diet and increased activity, documentation of current BMI, and an established diagnosis of moderate-to-severe OSA determined by Apnea-Hypopnea Index on polysomnography or a home sleep apnea test ^[6].

If the exception is approved for Zepbound, the prior authorization department enters an override and processes a test claim to make sure the prescription will pay at the pharmacy; both the member and prescriber are notified of the decision. In the GIC example, an approved Zepbound exception carried a tier 3 copay, while Mounjaro carried tier 2 ^[6]. If the exception is denied, the notice includes appeal instructions, the deadline, and what information is required, and the member may still fill the prescription at full cost ^[6].

What is the lawsuit over the Caremark removal?

A class action filed September 3, 2025 in the US District Court for the Southern District of New York alleges CVS Caremark breached its fiduciary duty under ERISA when it removed Zepbound, arguing that providers had deemed Zepbound medically necessary and that one plaintiff was later diagnosed with sleep apnea, a condition Zepbound is approved to manage ^[8].

The plaintiffs argue Zepbound and Wegovy are not clinically interchangeable because they are different molecules with different side effects and different approved indications ^[8]. Caremark called the suit without merit and said it intends to defend itself, noting that an exemption process exists ^[8].

Judge Louis L. Stanton has let the suit move forward, ruling that the plaintiffs, who were prescribed Zepbound for weight management and sleep apnea, validly alleged that Caremark flouted the terms of their health plans and engaged in self-dealing through a rebate agreement with Novo Nordisk ^[9]. No ruling on the merits has been made; these remain allegations ^[9][8].

Does Express Scripts cover Zepbound?

The 2026 Express Scripts National Preferred Formulary lists ZEPBOUND PEN [INJ] among its covered medications, alongside WEGOVY HD [INJ], WEGOVY PENS [INJ], WEGOVY TABLETS, FOUNDAYO, and MOUNJARO [INJ] ^[10].

But appearing on the list does not guarantee your plan pays. Express Scripts states that not all medications listed are covered by all prescription plans and directs members to check their benefit materials and call the number on their prescription ID card ^[10][11]. Express Scripts manages the plan for an employer, plan sponsor, health plan, or benefit fund, and that sponsor makes the final call ^[11].

For drugs that are excluded on the National Preferred Formulary, Express Scripts says a physician can request a coverage review for clinical reasons through its online portal at esrx.com/PA, and that additional covered alternatives may exist ^[11].

Does Optum Rx cover Zepbound?

The Optum Rx 2026 Premium Formulary, effective January 1, 2026, is set by a Pharmacy and Therapeutics Committee of doctors and pharmacists ^[12]. Optum Rx says that where differences exist between the formulary list and your benefit plan, the benefit plan documents rule, and that the formulary is not a complete list of covered medications ^[12].

For whether a specific medication is covered, at what tier, and under what conditions, Optum Rx directs members to call the number on their member ID card or check their plan’s website ^[12].

Does the reason for the prescription matter?

Yes. Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, and it is the only GLP-1 product approved for that use ^[8][6]. Lilly notes that Medicare coverage can vary by condition, listing obesity, overweight with weight-related medical problems, and moderate-to-severe OSA with obesity as distinct situations ^[15].

Plans treat the indications differently. In the IFEBP survey, 45% of employers cover GLP-1s for other FDA-approved conditions such as sleep apnea and cardiovascular disease ^[4]. But when Caremark removed Zepbound in 2025, it removed it for the OSA indication too, and existing OSA prior authorizations were transitioned to Wegovy, with all members regardless of indication required to try and fail Wegovy first before accessing tirzepatide ^[6].

The indication on the prescription is the prescriber’s determination.

Why does the pen type matter for coverage and price?

Zepbound comes in different presentations, and they are not treated the same way. The Express Scripts 2026 formulary lists ZEPBOUND PEN [INJ] specifically ^[10]. Lilly’s pricing also splits by presentation: the $25 savings-card price applies to the single-dose Pen for commercially insured patients with coverage, while the $299 price applies to the KwikPen or vial, not the single-dose Pen ^[15].

The KwikPen comes in 2.5, 5, 7.5, 10, 12.5, and 15 mg doses, with 2.5 mg as the starting dose that is not an approved maintenance dose, and pen needles are sold separately ^[15]. Lilly’s savings card defines a month as 28 days, covering up to 4 single-dose pens or 1 single-patient-use KwikPen ^[15].

What does prior authorization usually require?

Published criteria vary by plan, but common themes appear across sources. Restrictions often include a prior authorization or a BMI threshold of 40, well above the BMI of 30 that clinically defines obesity ^[2]. Marketplace carriers require 3 to 9 months of documented diet and exercise participation plus proof of failure to lose weight, mostly limited to BMI 40 and above ^[5]. Caremark requires a 6-month comprehensive weight-management program, BMI documentation, a reduced-calorie diet, and increased activity, with continuation tied to at least 5% weight loss ^[6]. Employers validate eligibility with objective biometric data and require weight-management program participation ^[3].

Even with coverage, some plans pay only a small share of the price, leaving members hundreds of dollars a month, and deductibles, including pharmacy-only deductibles, apply first ^[2][1].

How do I appeal a Zepbound denial?

Start with the denial notice. It is required to state the reason for the denial and the appeal deadline, and that document drives everything that follows ^[13].

Match the remedy to the denial type. A prior authorization denial is often fixable with better documentation from your prescriber. A formulary exclusion generally requires a separate formulary exception request. A step therapy requirement means the plan wants you to try the preferred drug first ^[13].

For an exception review, the documentation typically includes chart notes, lab results, and a letter of medical necessity showing an inadequate response or a contraindication to the preferred drug. In Caremark’s process, failure means the drug was tolerated but the response was inadequate ^[6]. If the exception is approved, the plan enters an override and runs a test claim before the pharmacy fill, and both member and prescriber are notified ^[6].

One limit: a formulary change is generally not a qualifying event that lets you switch plans mid-year. In the Massachusetts GIC example, members could not change medical plans after the Caremark removal because all GIC non-Medicare plans used the same drug benefit ^[6]. The Obesity Action Coalition, which receives financial support from drugmakers, notes that each carrier sets its own eligibility limits ^[2].

What if my employer excluded weight-loss drugs entirely?

An appeal usually cannot fix a category exclusion. Among employers not covering GLP-1s for weight loss, 83% exclude them through a carve-out from the medical and/or prescription drug plan, and only 9% are considering adding coverage ^[4].

Instead of drug coverage, these employers point to other benefits: disease or case management (74%), nutritional counseling (61%), bariatric surgery (61%), and lifestyle modification programs ^[4]. Some steer employees toward direct-to-consumer platforms (27%) or toward FSA, HSA, or integrated HRA dollars (21%) ^[4].

The trend is visible at large employers. Cigna stopped covering Zepbound and Wegovy for its own employees in June 2026, according to GoodRx citing Reuters ^[1]. NPR profiled a Massachusetts teacher who lost Zepbound coverage in July 2025, switched to Wegovy, then lost Wegovy coverage in October 2025 under the same employer plan, while her premium rose 20%; a University of Virginia obesity clinic reported that about 60% of its roughly 1,000 patients on obesity drugs pay out of pocket ^[2].

What do state employee plans show?

State plans illustrate how differently two employers can design the same benefit. Colorado state employee plans began covering weight-loss GLP-1s on May 1, 2026 under a GLP-1 Benefit 360 Program ^[14]. Members on the Cigna plan get only Zepbound for weight loss unless there is a medical necessity or allergy for another drug, with MedImpact handling exceptions, while Kaiser Permanente members keep access to all appropriate GLP-1s through Kaiser’s pre-authorization process ^[14]. The copay is $120, high-deductible plan members must meet their deductible first, a grandfathering provision ended May 1, 2026, and diabetes GLP-1 coverage is unchanged ^[14].

Massachusetts took the opposite path. The Group Insurance Commission, which covers over 220,000 subscribers and 460,000 members, followed the Caremark removal on July 1, 2025, and its GLP-1 weight-loss coverage is changing again as of July 1, 2026 ^[6].

What does Zepbound cost without insurance?

Lilly’s published prices depend on your insurance situation. Commercially insured patients with Zepbound coverage can get the single-dose Pen starting at $25 for up to a 3-month prescription through the Zepbound Savings Program ^[15]. Commercially insured patients without Zepbound coverage can get the KwikPen starting at $299 for a 1-month prescription ^[15]. People with no insurance can self-pay starting at $299 per month for the KwikPen or 4 vials; that $299 price is for the KwikPen or vial, not the single-dose Pen, and it is a starting price rather than the price for every dose ^[15].

For eligible Medicare Part D patients with a Zepbound prescription for weight management, Lilly offers the Medicare GLP-1 Bridge at no more than $50 per month, with eligibility based on the Bridge’s clinical criteria; Lilly states this is not a guarantee of coverage ^[15]. Coverage differs for Medicaid, VA, DoD, TRICARE, and other government programs ^[15].

The savings card excludes governmental beneficiaries, carries monthly and annual limits, is not insurance, and Lilly can end or change its terms at any time; HSA and FSA eligibility varies by plan ^[15].

Without coverage, out-of-pocket costs can exceed $1,400 a month ^[1]. One patient quoted by NPR paid Lilly’s $450 cash price for her dose of brand Zepbound and about $300 for a compounded version; compounded drugs are not FDA-approved generics, and brand-name drugmakers are trying to end obesity drug compounding ^[2].

A December 2025 report from the Institute for Clinical and Economic Review put tirzepatide at $57,779 per quality-adjusted life year compared with lifestyle modification alone, within commonly used value thresholds; the report frames budget impact, not value, as the plan-side problem ^[13].

Sources

1. GoodRx. Live updates: Insurance coverage for GIP and GLP-1 agonists like Zepbound & Wegovy in 2026.
2. NPR. Patients struggle to pay for obesity drugs as insurance coverage slips. April 22, 2026.
3. Business Group on Health. GLP-1 costs loom large for employers, forcing challenging coverage decisions, Business Group on Health survey finds.
4. Word on Benefits (International Foundation of Employee Benefit Plans). GLP-1 drugs survey report: What employers are—and aren’t—covering in 2026. July 7, 2026.
5. Becker’s Payer Issues. GLP-1 coverage under ACA plans continues to decline: 6 notes. December 2, 2025.
6. Massachusetts Group Insurance Commission. CVS Caremark decides to remove Zepbound from CVS Caremark formulary.
7. Truveta Research. Impact of the CVS GLP-1 formulary change: Trends in switching. September 5, 2025.
8. Fierce Healthcare. CVS Caremark hit with class-action lawsuit over decision to drop Zepbound from formulary. September 5, 2025.
9. Bloomberg Law. CVS Caremark ordered to defend lawsuit over Zepbound coverage.
10. Express Scripts. 2026 Express Scripts National Preferred Formulary.
11. Express Scripts. 2026 Express Scripts National Preferred Formulary Exclusions.
12. Optum Rx. 2026 Premium Formulary. Effective January 1, 2026.
13. Medical Daily. Denied coverage for Wegovy or Zepbound? Here is what the latest value assessment says about price and access. 2026.
14. Colorado Department of Human Resources. FAQs: GLP-1s for weight loss coverage change 2026. Effective May 1, 2026.
15. Eli Lilly. Savings & insurance options | Zepbound (tirzepatide).